Full text is available at the source.
Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses
Targeted delivery of mRNA and immune-activating molecules to the spleen to boost immune responses
AI simplified
Abstract
Spleen-selective mRNA vaccines induced a potent antigen-specific cytotoxic T cell immune response and prevented tumor growth in a mouse model.
- Spleen-targeted delivery of unmodified mRNA and TLR agonists resulted in a persistent antitumor cellular immune response.
- Lipid nanoparticles co-loaded with ovalbumin-coding mRNA and TLR4 agonists effectively facilitated tissue-specific mRNA expression in the spleen.
- The combination of mRNA antigens and TLR agonists enhanced Th1 immune responses by activating multiple Toll-like receptors.
- In a prophylactic mouse model, the vaccine prevented the growth of EG.7-OVA tumors and provided immune memory protection.
- The treatment also delayed tumor growth in subcutaneously transplanted lymphoma and reduced lung metastasis of melanoma.
AI simplified